BioCardia, Inc.
BCDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.02 | -0.04 | -0.02 |
| FCF Yield | -20,645.99% | -16.72% | -23.21% | -43.03% |
| EV / EBITDA | 3.37 | -4.71 | -2.53 | -1.98 |
| Quality | ||||
| ROIC | -45.57% | 179.75% | 406.87% | -129.81% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.13 | 0.80 | 0.60 | 1.12 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -86.97% | -64.99% |
| Free Cash Flow Growth | -1.33% | -1.98% | 37.14% | 1.49% |
| Safety | ||||
| Net Debt / EBITDA | 3.38 | 0.11 | 0.04 | 0.62 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -908.41 | -81.12 | -48.12 | -24.49 |